AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3029790 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate (SV) 800 mg
Number of subjects: 15
Study 3029790 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 31590686 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacies recruitment strategy
Number of subjects: 4013
Study 31590686 — intervention group
Group type: EXPERIMENTAL
Intervention: Paid media recruitment strategy
Number of subjects: 4013
Study 31590686 — intervention group
Group type: EXPERIMENTAL
Intervention: Word of mouth recruitment strategy
Number of subjects: 4013
Study 31590686 — intervention group
Group type: EXPERIMENTAL
Intervention: Unpaid media recruitment strategy
Number of subjects: 4013
Study 31590686 — intervention group
Group type: EXPERIMENTAL
Intervention: Seniors outreach recruitment strategy
Number of subjects: 4013
Study 31590686 — intervention group
Group type: EXPERIMENTAL
Intervention: Health care providers recruitment strategy
Number of subjects: 4013
Study 31590686 — intervention group
Group type: EXPERIMENTAL
Intervention: Media strategies
Number of subjects: 4013
Study 28664755 — intervention group
Group type: EXPERIMENTAL
Intervention: N‐LPA intervention using a tri‐axial accelerometer
Number of subjects: 38
Study 28664755 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 38
Study 28664755 — intervention group
Group type: EXPERIMENTAL
Intervention: LPA intervention
Number of subjects: 38
Study 28664755 — intervention group
Group type: EXPERIMENTAL
Intervention: N‐LPA intervention
Number of subjects: 38
Study 24923986 — intervention group
Group type: EXPERIMENTAL
Intervention: Yokukansan (YKS) 7.5 g/day
Number of subjects: 120
Study 24923986 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 22995543 — intervention group
Group type: EXPERIMENTAL
Intervention: Group PF (2 mg/kg propofol+1 mcg/kg fentanyl)
Number of subjects: 240
Study 22995543 — intervention group
Group type: EXPERIMENTAL
Intervention: Group P (2 mg/kg propofol alone)
Number of subjects: 240
Study 22995543 — intervention group
Group type: EXPERIMENTAL
Intervention: Group PMF (2 mg/kg propofol+1 mcg/kg fentanyl+0.02 mg/kg midazolam)
Number of subjects: 240
Study 22995543 — intervention group
Group type: EXPERIMENTAL
Intervention: Group E (0.2 mg/kg etomidate alone)
Number of subjects: 240
Study 22995543 — intervention group
Group type: EXPERIMENTAL
Intervention: Group EF (0.2 mg/kg etomidate+1 mcg/kg fentanyl)
Number of subjects: 240
Study 22995543 — intervention group
Group type: EXPERIMENTAL
Intervention: Group EMF (0.2 mg/kg etomidate+1 mcg/kg fentanyl+0.02 mg/kg midazolam)
Number of subjects: 240
Study 22995543 — intervention group
Group type: COMPARATOR
Intervention: Propofol groups (P, PF, PMF)
Number of subjects: 240
Study 22995543 — intervention group
Group type: COMPARATOR
Intervention: Etomidate groups (E, EF, EMF)
Number of subjects: 240
Study 22321279 — intervention group
Group type: EXPERIMENTAL
Intervention: tolvaptan 15 - 60 mg daily
Number of subjects: 65
Study 22321279 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 65
Study 19950759 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio-calcium from shells Pinctada maxima (260 mg of elemental calcium, three times a day)
Number of subjects: 50
Study 19950759 — intervention group
Group type: COMPARATOR
Intervention: Inorganic CaCO3 (500 mg daily)
Number of subjects: 50
Study 17101637 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation (AF) present at discharge with ischaemic heart disease
Number of subjects: 3587
Study 17101637 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation (AF) present at discharge without ischaemic heart disease
Number of subjects: 3587
Study 17101637 — intervention group
Group type: COMPARATOR
Intervention: Patients without atrial fibrillation (AF)
Number of subjects: 3587
Study 17101637 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with atrial fibrillation (AF)
Number of subjects: 3587
Study 15353386 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment strategy from professional sources (e.g., community agencies)
Number of subjects: 310
Study 15353386 — intervention group
Group type: COMPARATOR
Intervention: Recruitment strategy from non-professional sources (e.g., health fairs)
Number of subjects: 310
Study 15353386 — intervention group
Group type: COMPARATOR
Intervention: Recruitment strategy from advertisements
Number of subjects: 310
Study 12136614 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillator (ICD)
Number of subjects: 0
Study 12136614 — intervention group
Group type: COMPARATOR
Intervention: Antiarrhythmic agents (mainly amiodarone)
Number of subjects: 0
Study 9534006 — intervention group
Group type: EXPERIMENTAL
Intervention: Oscillations of cytoplasmic Ca2+ concentration [(Ca2+]i) in beta cells; specific dosage and duration not available.
Number of subjects: 0
Study 9534006 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin secretion; specific dosage and duration not available.
Number of subjects: 0
Study 7698624 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (40 mg daily) and Amoxicillin (1 g twice daily) for 2 weeks (Group A)
Number of subjects: 51
Study 7698624 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole (40 mg daily) alone for 2 weeks (Group B)
Number of subjects: 51
Study 2541754 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 0
Study 2541754 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 793305 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium citrate (Litarex)
Number of subjects: 18
Study 793305 — intervention group
Group type: COMPARATOR
Intervention: Lithium sulphate (Lithionit Durettes)
Number of subjects: 18
Study 30558758 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 1104
Study 30558758 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 1104
Study 30558758 — intervention group
Group type: COMPARATOR
Intervention: Optimized medical therapy (OMT)
Number of subjects: 1104
Study 30558758 — intervention group
Group type: EXPERIMENTAL
Intervention: Propensity score-matched CABG
Number of subjects: 1104
Study 30558758 — intervention group
Group type: EXPERIMENTAL
Intervention: Propensity score-matched PCI
Number of subjects: 1104
Study 27813225 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative ultrasound (US) performed immediately before surgery by a radiologist accompanied by the surgeon.
Number of subjects: 154
Study 27813225 — intervention group
Group type: COMPARATOR
Intervention: Control group (no preoperative ultrasound).
Number of subjects: 154
Study 25880052 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline 400 mg three times a day for 3 days before operation
Number of subjects: 178
Study 23996340 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole (30 mg/day) for 4 weeks
Number of subjects: 69
Study 23996340 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole (30 mg/day) for 8 weeks
Number of subjects: 69
Study 21093496 — intervention group
Group type: EXPERIMENTAL
Intervention: MV+DTP+OPV
Number of subjects: 568
Study 21093496 — intervention group
Group type: COMPARATOR
Intervention: MV+OPV
Number of subjects: 568
Study 19407472 — intervention group
Group type: EXPERIMENTAL
Intervention: WGHFB (government funding and family support)
Number of subjects: 71
Study 19407472 — intervention group
Group type: COMPARATOR
Intervention: WGHFA (self-financed care)
Number of subjects: 71
Study 17445902 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromfenac ophthalmic solution 0.09% (Xibrom)
Number of subjects: 527
Study 17445902 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 527
Study 15064599 — intervention group
Group type: COMPARATOR
Intervention: High carbohydrate meal (HC)
Number of subjects: 24
Study 15064599 — intervention group
Group type: COMPARATOR
Intervention: Moderate fat meal (MF)
Number of subjects: 24
Study 15064599 — intervention group
Group type: EXPERIMENTAL
Intervention: High carbohydrate meal (HC) and Moderate fat meal (MF)
Number of subjects: 24
Study 11254817 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (budesonide, beclomethasone dipropionate)
Number of subjects: 374
Study 11254817 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide
Number of subjects: 374
Study 11254817 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate
Number of subjects: 374
Study 11254817 — intervention group
Group type: COMPARATOR
Intervention: Non-corticosteroid treatment (reference group)
Number of subjects: 374
Study 9881085 — intervention group
Group type: EXPERIMENTAL
Intervention: D10 Group (10 mg dexamethasone)
Number of subjects: 44
Study 9881085 — intervention group
Group type: EXPERIMENTAL
Intervention: D20 Group (20 mg dexamethasone)
Number of subjects: 44
Study 9881085 — intervention group
Group type: EXPERIMENTAL
Intervention: D2 Group (not specified dexamethasone dosage)
Number of subjects: 44
Study 9881085 — intervention group
Group type: EXPERIMENTAL
Intervention: Male patients
Number of subjects: 44
Study 9881085 — intervention group
Group type: EXPERIMENTAL
Intervention: Female patients
Number of subjects: 44
Study 8024942 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally similar video (CSV) AIDS education
Number of subjects: 0
Study 8024942 — intervention group
Group type: COMPARATOR
Intervention: Culturally dissimilar video (CDV) AIDS education
Number of subjects: 0
Study 28960244 — intervention group
Group type: EXPERIMENTAL
Intervention: Case-only approach for measuring markers predicting treatment effects
Number of subjects: 0
Study 28960244 — intervention group
Group type: EXPERIMENTAL
Intervention: Markers measured in cases only
Number of subjects: 0
Study 29441973 — intervention group
Group type: EXPERIMENTAL
Intervention: Angelica dahurica dressing (continuous application for 4 weeks)
Number of subjects: 98
Study 29441973 — intervention group
Group type: EXPERIMENTAL
Intervention: Angelica dahurica dressing
Number of subjects: 98
Study 29441973 — intervention group
Group type: COMPARATOR
Intervention: Compound clotrimazole cream (control)
Number of subjects: 98
Study 24726635 — intervention group
Group type: EXPERIMENTAL
Intervention: Clevidipine
Number of subjects: 1410
Study 24726635 — intervention group
Group type: COMPARATOR
Intervention: Control (Nitroglycerin, Sodium Nitroprusside, Nicardipine)
Number of subjects: 1410
Study 24726635 — intervention group
Group type: EXPERIMENTAL
Intervention: AUC≤10 mmHg×min/h
Number of subjects: 1410
Study 22404883 — intervention group
Group type: COMPARATOR
Intervention: Repeated short-term exposure to +22°C for up to three periods of 3 h on days 3, 8, and 15 of storage, followed by a 5 h exposure on day 29.
Number of subjects: 0
Study 22404883 — intervention group
Group type: COMPARATOR
Intervention: Repeated short-term exposure to -2°C for up to three periods of 3 h on days 3, 8, and 15 of storage, followed by a 5 h exposure on day 29.
Number of subjects: 0
Study 22404883 — intervention group
Group type: COMPARATOR
Intervention: Exposure of RCC to 25°C for 24 h from day 2.
Number of subjects: 0
Study 22404883 — intervention group
Group type: COMPARATOR
Intervention: Exposure of RCC to 25°C for 48 h from day 2.
Number of subjects: 0
Study 19520901 — intervention group
Group type: EXPERIMENTAL
Intervention: Shame transformation treatment program
Number of subjects: 0
Study 19520901 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 18420852 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 1 mg
Number of subjects: 244
Study 18420852 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron 4 mg
Number of subjects: 244
Study 16388832 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone 100 mg
Number of subjects: 8
Study 16388832 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 12728422 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial parapatellar approach with tourniquet application
Number of subjects: 10
Study 12728422 — intervention group
Group type: EXPERIMENTAL
Intervention: Midvastus approach with tourniquet application
Number of subjects: 10
Study 12728422 — intervention group
Group type: EXPERIMENTAL
Intervention: Midvastus approach after tourniquet deflation
Number of subjects: 10
Study 11115460 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (0.27 mmol/kg body weight) infused IV over 20 min
Number of subjects: 22
Study 11115460 — intervention group
Group type: COMPARATOR
Intervention: Isotonic glucose infusion
Number of subjects: 22
Study 8784112 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirilazad mesylate, 6 mg/kg per day for 3 days
Number of subjects: 660
Study 8784112 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 660
Study 1628130 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentaglobin (IgM and IgA enriched intravenous immunoglobulin)
Number of subjects: 63
Study 1628130 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentaglobin
Number of subjects: 63
Study 6381968 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestrogen/progestogen + Calcium (0.5 g daily)
Number of subjects: 17
Study 6381968 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Calcium (0.5 g daily)
Number of subjects: 17
Study 31714324 — intervention group
Group type: EXPERIMENTAL
Intervention: VR (Virtual Reality)
Number of subjects: 8
Study 31714324 — intervention group
Group type: EXPERIMENTAL
Intervention: VR enhanced (Visual feedback overstated)
Number of subjects: 8
Study 31714324 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up
Number of subjects: 8
Study 31714324 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 8
Study 30142847 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion with behavioral training (8 to 12 sessions during the first 4 weeks)
Number of subjects: 0
Study 30142847 — intervention group
Group type: COMPARATOR
Intervention: Behavioral training only (first 4 weeks)
Number of subjects: 0
Study 30142847 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion
Number of subjects: 0
Study 26210308 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D Fluoronavigation
Number of subjects: 143
Study 26210308 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgical procedure (Group C)
Number of subjects: 143
Study 24751323 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydrotestosterone (DHT) 70 mg daily transdermal treatment
Number of subjects: 114
Study 24751323 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel treatment
Number of subjects: 114
Study 22282542 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counseling (self‐help materials and up to six counseling sessions)
Number of subjects: 2277
Study 22282542 — intervention group
Group type: COMPARATOR
Intervention: Self‐help (self‐help materials only)
Number of subjects: 2277
Study 20802287 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertrophy-intensity group (3 sets of 12 repetitions at 70% of 1RM)
Number of subjects: 16
Study 20802287 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength-intensity group (3 sets of 6 repetitions at 85% of 1RM)
Number of subjects: 16
Study 18468013 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalational anesthetic regimen (group A)
Number of subjects: 784
Study 18468013 — intervention group
Group type: COMPARATOR
Intervention: Non-inhalational anesthetic regimen (group B)
Number of subjects: 784
Study 15939028 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration approach (endogenous control)
Number of subjects: 0
Study 15939028 — intervention group
Group type: COMPARATOR
Intervention: Control approach (exogenous trigger)
Number of subjects: 0
Study 12905557 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with acute rejection episodes
Number of subjects: 52
Study 12905557 — intervention group
Group type: COMPARATOR
Intervention: Patients without acute rejection episodes
Number of subjects: 52
Study 10568558 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacemaker therapy
Number of subjects: 0
Study 10568558 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporary pacing during tilt-table testing
Number of subjects: 0
Study 10568558 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent pacing
Number of subjects: 0
Study 10568558 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate-drop responsiveness
Number of subjects: 0
Study 8732120 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy plus systemic interleukin 2 (IL‐2)
Number of subjects: 200
Study 8732120 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus radiotherapy
Number of subjects: 200
Study 8732120 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus radiation and IL‐2
Number of subjects: 200
Study 8732120 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 200
Study 1744911 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice of coping strategies
Number of subjects: 0
Study 1744911 — intervention group
Group type: COMPARATOR
Intervention: Assigned coping strategy
Number of subjects: 0
Study 1744911 — intervention group
Group type: EXPERIMENTAL
Intervention: High internal health locus of control
Number of subjects: 0
Study 1744911 — intervention group
Group type: EXPERIMENTAL
Intervention: External health locus of control
Number of subjects: 0
Study 6609268 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellulose acetate (CA) hemodialysis membranes
Number of subjects: 0
Study 6609268 — intervention group
Group type: COMPARATOR
Intervention: Cuprophan (Cu) hemodialysis membranes
Number of subjects: 0
Study 30508996 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective saddle rhizotomy using thermal radiofrequency ablation of S3 on one side and bilateral ablation of S4 and S5 (RF group, n = 20)
Number of subjects: 40
Study 30508996 — intervention group
Group type: COMPARATOR
Intervention: Conventional chemical rhizotomy using hyperbaric 6% phenol in glycerin (Phenol group, n = 20)
Number of subjects: 40
Study 26795622 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 % chlorhexidine digluconate (CHX)/herbal extract combination
Number of subjects: 40
Study 26795622 — intervention group
Group type: COMPARATOR
Intervention: 0.1 % chlorhexidine solution
Number of subjects: 40
Study 25515666 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilization surgery followed by physiotherapy rehabilitation
Number of subjects: 140
Study 25515666 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy rehabilitation alone
Number of subjects: 140
Study 22378155 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral lisinopril 2.5 mg (n = 17)
Number of subjects: 33
Study 22378155 — intervention group
Group type: COMPARATOR
Intervention: Daily oral placebo (n = 16)
Number of subjects: 33
Study 21076717 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/day folic acid supplementation
Number of subjects: 20
Study 21076717 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 18801859 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-extremity exercise and walking intervention program
Number of subjects: 79
Study 18801859 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=38)
Number of subjects: 79
Study 18801859 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received diabetic foot care education and regular foot care
Number of subjects: 79
Study 15886721 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone 6 mg/day for 12 weeks
Number of subjects: 78
Study 15886721 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol 20 mg/day for 12 weeks
Number of subjects: 78
Study 15886721 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 78
Study 14989068 — intervention group
Group type: EXPERIMENTAL
Intervention: Dan Shao Tang (DST) and western medicine
Number of subjects: 90
Study 14989068 — intervention group
Group type: COMPARATOR
Intervention: Western medicine
Number of subjects: 90
Study 10834778 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous thoracic epidural analgesia with bupivacaine-fentanyl (CEA)
Number of subjects: 33
Study 10834778 — intervention group
Group type: COMPARATOR
Intervention: Intravenous patient-controlled analgesia with morphine sulfate (PCA)
Number of subjects: 33
Study 9105543 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam (7.5-30 mg)
Number of subjects: 78
Study 9105543 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam (various formulations)
Number of subjects: 78
Study 8371127 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin suspension 7.5 mg/kg bodyweight twice daily
Number of subjects: 145
Study 8371127 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin suspension 125 mg (bodyweight < 25 kg) or 250 mg (bodyweight ≥ 25 kg) three times a day
Number of subjects: 145
Study 3524488 — intervention group
Group type: EXPERIMENTAL
Intervention: Papaverine 60 mg added to cold cardioplegia
Number of subjects: 495
Study 3524488 — intervention group
Group type: COMPARATOR
Intervention: Cold cardioplegia without papaverine
Number of subjects: 495
Study 30709324 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic
Number of subjects: 16
Study 30709324 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 29326021 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple rTMS protocol on the left dorsolateral prefrontal cortex (lDLPFC)
Number of subjects: 19
Study 29326021 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex rTMS protocol using six regions of interest
Number of subjects: 19
Study 26282062 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxacalcitol topical ointment (22‐oxacalcitriol [OCT]), applied twice daily for 8 weeks
Number of subjects: 188
Study 26282062 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 188
Study 26282062 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxacalcitol topical ointment (22‐oxacalcitriol [OCT])
Number of subjects: 188
Study 24256098 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementary transcatheter arterial embolization (STAE) performed after achieved endoscopic hemostasis
Number of subjects: 105
Study 24256098 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (control group)
Number of subjects: 105
Study 24256098 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementary transcatheter arterial embolization (STAE)
Number of subjects: 105
Study 22307384 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriflunomide 7 mg/day
Number of subjects: 179